Oxford Nanopore Technologies

Oxford Nanopore Technologies, a UK-based pharmaceutical preparation manufacturer, is actively addressing its carbon emissions and has established ambitious climate commitments.

For 2025, the company projects its total greenhouse gas emissions to be approximately 77.06 million kg CO2e. This includes about 334,000 kg CO2e from Scope 1 emissions, 1.331 million kg CO2e from Scope 2 (location-based), and roughly 75.385 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions in 2025 are expected to be purchased goods and services (approximately 53.044 million kg CO2e), capital goods (approximately 12.448 million kg CO2e), and business travel (approximately 2.992 million kg CO2e).

Looking back, in 2024, Oxford Nanopore Technologies's total emissions were about 91.534 million kg CO2e, comprising approximately 313,000 kg CO2e from Scope 1, 1.21 million kg CO2e from Scope 2 (location-based), and around 90.011 million kg CO2e from Scope 3. In 2022, the company reported total emissions of approximately 56.638 million kg CO2e, with Scope 1 emissions at roughly 592,000 kg CO2e, Scope 2 (location-based) at about 959,000 kg CO2e, and Scope 3 at approximately 54.495 million kg CO2e.

Oxford Nanopore Technologies has set Science Based Targets initiative (SBTi) validated targets. It aims to achieve net-zero greenhouse gas emissions across its entire value chain by 2045. For near-term reductions, the company is committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, using 2023 as a base year. Furthermore, it intends to reduce Scope 3 GHG emissions by 52% per GBP value added within the same timeframe. Long-term, the company targets at least a 90% absolute reduction in Scope 1, 2, and 3 GHG emissions by 2045, also from a 2023 baseline.